NASDAQ:PETS

PetMed Express Stock Forecast, Price & News

$27.33
+0.03 (+0.11 %)
(As of 09/23/2021 04:00 PM ET)
Add
Compare
Today's Range
$27.16
$28.26
50-Day Range
$26.50
$31.39
52-Week Range
$24.75
$57.00
Volume230,975 shs
Average Volume683,680 shs
Market Capitalization$556.14 million
P/E Ratio20.10
Dividend Yield4.40%
Beta0.54
30 days | 90 days | 365 days | Advanced Chart
Receive PETS News and Ratings via Email

Sign-up to receive the latest news and ratings for PetMed Express and its competitors with MarketBeat's FREE daily newsletter.


PetMed Express logo

About PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.00 out of 5 stars

Retail/Wholesale Sector

149th out of 263 stocks

Drug Stores & Proprietary Stores Industry

4th out of 10 stocks

Analyst Opinion: 3.0Community Rank: 3.1Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











PetMed Express (NASDAQ:PETS) Frequently Asked Questions

Is PetMed Express a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PetMed Express stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PETS, but not buy additional shares or sell existing shares.
View analyst ratings for PetMed Express
or view top-rated stocks.

What stocks does MarketBeat like better than PetMed Express?

Wall Street analysts have given PetMed Express a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PetMed Express wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is PetMed Express' next earnings date?

PetMed Express is scheduled to release its next quarterly earnings announcement on Monday, October 25th 2021.
View our earnings forecast for PetMed Express
.

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) announced its earnings results on Sunday, July, 25th. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by $0.12. The business earned $79.31 million during the quarter. PetMed Express had a trailing twelve-month return on equity of 20.09% and a net margin of 9.33%.
View PetMed Express' earnings history
.

How has PetMed Express' stock price been impacted by COVID-19 (Coronavirus)?

PetMed Express' stock was trading at $25.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PETS stock has increased by 5.3% and is now trading at $27.33.
View which stocks have been most impacted by COVID-19
.

How often does PetMed Express pay dividends? What is the dividend yield for PetMed Express?

PetMed Express announced a quarterly dividend on Monday, July 26th. Investors of record on Friday, August 6th will be given a dividend of $0.30 per share on Friday, August 13th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 4.39%. The ex-dividend date of this dividend is Thursday, August 5th.
View PetMed Express' dividend history
.

Is PetMed Express a good dividend stock?

PetMed Express pays an annual dividend of $1.20 per share and currently has a dividend yield of 4.40%. PETS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View PetMed Express' dividend history.

What price target have analysts set for PETS?

1 Wall Street analysts have issued 1-year price objectives for PetMed Express' stock. Their forecasts range from $39.00 to $39.00. On average, they expect PetMed Express' share price to reach $39.00 in the next year. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for PetMed Express
or view top-rated stocks among Wall Street analysts.

Who are PetMed Express' key executives?

PetMed Express' management team includes the following people:
  • Matthew N. Hulett, President, Chief Executive Officer & Director
  • Bruce S. Rosenbloom, Chief Financial Officer & Treasurer
  • Alison Berges, Secretary & General Counsel

What is Mendo Akdag's approval rating as PetMed Express' CEO?

5 employees have rated PetMed Express CEO Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among PetMed Express' employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of PetMed Express' key competitors?

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

What is PetMed Express' stock symbol?

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

Who are PetMed Express' major shareholders?

PetMed Express' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jefferies Group LLC (0.00%), BlackRock Inc. (15.36%), ProShare Advisors LLC (8.04%), Vanguard Group Inc. (6.97%), State Street Corp (4.93%) and Renaissance Technologies LLC (4.29%). Company insiders that own PetMed Express stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends for PetMed Express
.

Which institutional investors are selling PetMed Express stock?

PETS stock was sold by a variety of institutional investors in the last quarter, including Penserra Capital Management LLC, Millennium Management LLC, Renaissance Technologies LLC, BlackRock Inc., Formidable Asset Management LLC, Dimensional Fund Advisors LP, AQR Capital Management LLC, and Hussman Strategic Advisors Inc.. Company insiders that have sold PetMed Express company stock in the last year include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag, and Ronald J Korn.
View insider buying and selling activity for PetMed Express
or view top insider-selling stocks.

Which institutional investors are buying PetMed Express stock?

PETS stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, ProShare Advisors LLC, State Street Corp, Group One Trading L.P., Walleye Trading LLC, Goldman Sachs Group Inc., Amundi, and North Star Investment Management Corp..
View insider buying and selling activity for PetMed Express
or or view top insider-buying stocks.

How do I buy shares of PetMed Express?

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetMed Express' stock price today?

One share of PETS stock can currently be purchased for approximately $27.33.

How much money does PetMed Express make?

PetMed Express has a market capitalization of $556.14 million and generates $309.21 million in revenue each year.

How many employees does PetMed Express have?

PetMed Express employs 219 workers across the globe.

When was PetMed Express founded?

PetMed Express was founded in 1996.

What is PetMed Express' official website?

The official website for PetMed Express is www.1800petmeds.com.

Where are PetMed Express' headquarters?

PetMed Express is headquartered at 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445.

How can I contact PetMed Express?

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at (561) 526-4444.


This page was last updated on 9/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.